USPTO serial 79440017
JUST-AAV
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- MESSICK, TABITHA LEE
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 686 means your mark is published in the USPTO Official Gazette and in the 30-day opposition period. If no opposition is filed, prosecution typically continues toward registration or a Notice of Allowance. Monitor the opposition window. After it closes, watch for Notice of Allowance (intent-to-use) or registration (use-based).
Need help with JUST-AAV?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Kumiko Ide
Kumiko Ide Wenderoth, Lind & Ponack, L.L.P.1150 Connecticut Avenue, NW, Suite 505Washington, DC 20036United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals for use in industry and science; diagnostic reagents for scientific or research use; biological preparations for use in industry and science; chemical reagents, other than for medical or veterinary purpose; biochemical reagents used for non-medical purposes; diagnostic reagents and preparations, except for medical or veterinary use; chemical reagents for use in genetic research, other than for medical or veterinary use; chemicals and biochemical products for use in gene delivery technology, other than for medical or veterinary use; active chemical ingredients for use in the manufacture of pharmaceuticals; biological materials, namely, adeno-associated viruses (AAVs), AAV particles and AAV plasmids, all for scientific and research purposes and not for medical and veterinary purposes; biological materials, namely, viral vectors in the nature of genetically modified viruses for scientific and research purposes; adeno-associated virus (AAV) vectors, protein sequences and nucleic acid sequences for use in scientific research and pharmaceutical research, other than medical or veterinary purposes; nucleic acid sequences, other than for medical or veterinary purposes | ACTIVE | — |
| 005 | Pharmaceutical preparations for gene therapy for the treatment of genetic diseases or disorders; pharmaceutical preparations for use in the treatment of gene therapy treatable diseases; pharmaceutical preparations containing adeno-associated virus (AAV) protein sequences and nucleic acid sequences for use in gene delivery; therapeutic drugs and agents in the nature of viral vectors in the form of injectable pharmaceutical preparations for use in the treatment of growth hormone deficiency, lysosomal disease and renal anemia; therapeutic drugs and agents in the nature of viral vectors in the form of injectable pharmaceutical preparations for applications in regenerative medicine; chemotherapeutics; organotherapy preparations; biological preparations for gene therapy for the treatment of genetic diseases or disorders; biological preparations for use in the treatment of gene therapy treatable diseases; gene therapy products, namely, biopharmaceutical preparations primarily composed of adeno-associated virus (AAV) vectors comprising of a transgene or other nucleic acid payload for delivery to a cell or tissue; biological preparations for gene therapy; reagents for medical or veterinary purposes; antibodies for medical or veterinary purposes; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; pharmaceutical preparations containing viral vectors for medical use relating to gene therapy; gene therapy preparations for treatment of neurological diseases; pharmaceutical preparations acting on the central nervous system; nucleic acid sequences for medical and veterinary purposes; cells for medical or clinical use; enzymes for medical purposes | ACTIVE | — |
| 042 | Medical research; chemical research; testing, inspection or research in the field of chemistry; chemical analysis; medical and scientific research, namely, conducting clinical trials for others; testing, inspection or research of pharmaceuticals; gene therapy research; development of gene-based medicines; research and development services relating to medicines; research and development in the field of biotechnology; development of new technology for others in the field of medicine, science, and chemistry; research and development of new products for others; laboratory services for biomanufacturing; scientific research; providing medical and scientific research information in the field of pharmaceuticals; research and development services in the field of platform technologies for genetic delivery of therapies and pharmaceuticals; technological consultation and scientific research in the field of gene delivery technology; technological consultation and scientific research in the field of drug delivery technology; research and development of vaccines; quality control for others | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by JCR Pharmaceuticals Co., Ltd.
- Other trademarks owned by JCR Pharmaceuticals Co., Ltd.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named JUST-AAV
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 22, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 22, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 17, 2026 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Sep 16, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 2, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Sep 2, 2026 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Aug 22, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 21, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 21, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 21, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 19, 2026 | RFNT | REFUSAL PROCESSED BY IB | — |
| Feb 27, 2026 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Feb 27, 2026 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jan 31, 2026 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jan 30, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 21, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 20, 2026 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jan 20, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 18, 2026 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Dec 25, 2025 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |